2020
DOI: 10.1016/j.msard.2020.102592
|View full text |Cite
|
Sign up to set email alerts
|

Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment

Abstract: Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) represents a demyelinating disorder for which tocilizumab, an anti-IL6 receptor, has been tested to prevent disabling relapses. In a subgroup of patients affected with novel Coronavirus disease (COVID-19), tocilizumab has also increased the survival rate. We present the case of a 31-years-old Caucasian patient who experienced an almost asymptomatic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection during treatment with tocilizumab,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
3
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 6 publications
0
3
1
Order By: Relevance
“…Masuccio et al described a 31-year-old female with MOG NMOSD who had a three-day history of anosmia and generalized myalgia with positive nasopharyngeal swabs. COVID-19 did not impact on her walking abilities, considering she had moderate previous paraparesis [12]. Both previously reported MNO cases were younger and less disabled compared with the patient of our report, but globally all three of them had a mild SARS-CoV-2 infection.…”
Section: Discussioncontrasting
confidence: 40%
“…Masuccio et al described a 31-year-old female with MOG NMOSD who had a three-day history of anosmia and generalized myalgia with positive nasopharyngeal swabs. COVID-19 did not impact on her walking abilities, considering she had moderate previous paraparesis [12]. Both previously reported MNO cases were younger and less disabled compared with the patient of our report, but globally all three of them had a mild SARS-CoV-2 infection.…”
Section: Discussioncontrasting
confidence: 40%
“…13,14 As AQP4-IgG+ NMOSD and MOGAD both display antibody-and complement-mediated CNS injury and similar inflammatory CSF profiles (with elevated IL-6), 27,28 IL6-blockade may also be beneficial in MOGAD, supported by recent case reports. 23,25,26,[29][30][31][32][33] This retrospective multicenter study explored the safety and efficacy of TCZ in patients with MOGAD and is able to connect these findings with the effects of TCZ in classical (i.e., AQP4-IgG+) or double-seronegative NMOSD.…”
Section: Discussionmentioning
confidence: 99%
“…47 Compared with untreated adult patients with MOGAD, AZA, MMF, and RTX, but not MTX, mitoxantrone, and cyclophosphamide, significantly reduced the risk of new relapses and the ARR in a cohort of 125 patients. 48 So far, only 14 different MOGAD patients, treated IV and/or subcutaneously with TCZ, were reported in 7 small case reports/series 23,26,[29][30][31][32][33] ; 6 of these 14 patients were included in the present cohort.…”
Section: Discussionmentioning
confidence: 99%
“…Given the high risk of relapse, the patient continued taking tocilizumab, and the symptoms stabilized. The patient also retained walking ability ( 58 ).…”
Section: Tocilizumabmentioning
confidence: 92%